Clinical Research Directory

Inclusion Criteria: * Aged 18 to 75 years (inclusive), male or female. * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2. * Life expectancy of ≥ 3 months. * Histologically or cytologically confirmed malignant solid tumors. * Investigator-confirmed diagnosis of CIPN accompanied with chemotherapy. * Adequate organ function. Exclusion Criteria: * Presence of any type of peripheral neuropathy other than CIPN (e.g., diabetic, paraneoplastic, or nutritional). * Toxicities from prior anti-tumor therapy (excluding CIPN) \> CTCAE Grade 1 within 2 weeks of first dose (excluding alopecia, skin pigmentation, stable hypothyroidism, or chronic events). * Participants with any of the following cardiovascular diseases or medical history: 1. Ischemic heart disease or myocardial infarction, unstable angina, coronary artery spasm, congestive heart failure (NYHA Class III-IV), cardiac arrest, stroke, or transient ischemic attack within 6 months; 2. Other clinically significant cardiac disorders per investigator's judgment. * Presence of active systemic infections. * History of or active primary/secondary immunodeficiency. * Participation in an interventional clinical trial within 1 month prior to screening. * Hypersensitivity to any component of the study drug (and its excipients). * Any condition deemed by the investigator to pose excessive risk, confound results, or interfere with compliance.